Abstract:This article highlights the potential of azole derivatives in cancer therapy, focusing on their ability to target cancer cells and disrupt key biological pathways. It discusses recent advances, structural modifications, and ongoing research aimed at enhancing their anticancer efficacy. The review accentuates the therapeutic promise of azoles in developing innovative treatments for cancer. Monocyclic 5‐membered heterocycles including imidazoles, thiazoles, oxazoles, and their related compounds have gained significant attention in medicinal chemistry because of their potent anticancerous activity. These small heterocyclic molecules possess versatile properties, including biological activity, absorption, distribution, metabolism, excretion, and chemical diversity that give them immense potential as anticancer agents. It is also a fact that inherent characteristic of azoles to combine with many biological molecules through hydrogen bond, stacking, and hydrophobic interaction makes them effective against almost all cancer types. In the present paper the author discusses the way which is connected with chemical structure of monocyclic azoles and their anticancer activity namely the ability of these compounds to intercalate with DNA, to inhibit some enzymes and to interfere cellular signaling pathways. Interestingly, several azole derivatives have been seen to be effective in preclinical efficacy studies as well as in clinical trials and are considered to be potent in overcoming the problem of resistance and side effects of the common anticancer agents. As the synthetic chemistry progresses, the structural system of the azoles has diversified and development in the pharmacology has become more specific. This has helped in enhancing the formation of new molecules in the azole class with improved selectivity and efficacy. Furthermore, the comprehensive review explains how computational chemistry and structure‐activity relationship (SAR) approaches are applied to the design of future‐generation azole compounds. In light of these facts, this article is designed to give a broad overview of the current state of monocyclic azole‐based anticancer agents in an attempt to further assert its therapeutic promise and spur further attempts at infusing the said agents into the cancer therapeutics fray. The discoveries made in this study may allow the development the radical different therapeutic approaches, which could lead to improved and targeted treatment of cancer.

A decade's overview of 2‐aminothiophenes and their fused analogs as promising anticancer agents

Synthetic and anti-cancer activity aspects of 1, 3, 4-thiadiazole containing bioactive molecules: A concise review

1,2,3‐Triazole hybrids as anticancer agents: A review

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

Synthesis Of Some Novel Thiophene Analogues As Potential Anticancer Agents

Thiazole moiety: A promising scaffold for anticancer drug discovery

2-Aminobenzothiazoles in anticancer drug design and discovery

Recent review on 1,3-thiazole derivatives as therapeutic targeted for anticancer activity

Medicinal attributes of thienopyrimidine scaffolds incorporating the aryl urea motif as potential anticancer candidates via VEGFR inhibition

Naphthalimides and Analogues As Antitumor Agents:A Review on Molecular Design, Bioactivity and Mechanism of Action

In the pursuit of novel therapeutic agents: synthesis, anticancer evaluation, and physicochemical insights of novel pyrimidine-based 2-aminobenzothiazole derivatives

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects

Advances in the Discovery of Anthraquinone-Based Anticancer Agents

Azole Derivatives: Cutting‐Edge Agents in Cancer Therapy

Advances in 2‐substituted benzothiazole scaffold‐based chemotherapeutic agents

Design, Synthesis, Cytotoxic Screening and Molecular Docking Studies of Novel Hybrid Thiosemicarbazone Derivatives as Anticancer Agents

Recent Progress of Sulfonamide-Indole/Carbazole Hybrids with the Anticancer Potential (A Review)

Synthesis and molecular docking of some new thiazolidinone and thiadiazole derivatives as anticancer agents

Overview of naphthalimide analogs as anticancer agents.

Tetrahydrocarbazoles incorporating 5-arylidene-4-thiazolinones as potential antileukemia and antilymphoma targeting tyrosine kinase and tubulin polymerase enzymes: Design, synthesis, structural, biological and molecular docking studies

An update of new small-molecule anticancer drugs approved from 2015 to 2020